(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Most Vital Crossroads in Olympic History - 2In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 3Manual for Conservative SUVs For Seniors
- 4Gov’t approves millions for border cities in North under Hezbollah fire
- 5The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Pick Your Favored method of transportation
- Canada cancels its 1st moon rover: 'It's hopefully not a lost cause'
- How to see the Ursids, the final meteor shower of 2025
- When faith comes under fire: How Iran’s repression of religious minorities has increased
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- Don't miss these five impressive spots in Bangkok
- 23 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- Tesla plans to expand production at German car plant
- Must-Sit in front of the Programs from Europe and the US
